“That’s bad...

...No that’s good!”

“That’s bad...

... No that’s good!”
"Payer refuses to refund patient when drug company refunds payer for the same drug in a value based contract"
THE BAD

• Contradictions
  – Access - closing practices
  – More biosimilars – minimal incentives to use
  – Payment parity – different reimbursement systems
  – Notification of drug prices – which price
  – Patient Financial Assistance – Inadequate Foundation funds
  – Need for value – Utilization based system
THE BAD

• Guardrails that stop or restrict forward movement and progress
THE BAD

• Incomplete ‘value based’ arrangements
  – Manufacturers
  – Providers
  – Payers
  – But where are the patients?
THE GOOD

• Better understanding of the issues
• Progress in addressing the issues
• Spotlight 4 regional initiatives
• Mention of many others